Abstract
During the coronavirus disease 2019 (COVID-19) pandemic researchers looked for evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in feces dissolved in wastewater samples to assess levels of infection across communities. This activity is known colloquially as sewer monitoring and called wastewater-based epidemiology in academic settings. When used for public health surveillance in the United States, wastewater monitoring is not regulated, although general ethical principles have been described. Prior to this study, no nationwide data existed regarding the public’s perceptions of wastewater being used for community health monitoring. Using an online survey distributed to a representative sample of adults in the Unites States (N=3,083), we investigated the public’s perceptions regarding what is monitored, where monitoring occurs, and privacy concerns related to wastewater monitoring as a public health surveillance tool. Further, the Privacy Attitudes Questionnaire assessed respondents’ general privacy boundaries. The results suggest that respondents supported using wastewater for health monitoring, but within some bounds. Participants were most likely to support or strongly support monitoring for disease (95%), environmental toxins (94%), and terroristic threats (90%, e.g., anthrax). Two-thirds of respondents endorsed no prohibition to locations being monitored while the most common category of location respondents wanted to be prohibited from monitoring was personal residencies. Additionally, the findings suggest that those younger in age and living in an urban area were more supportive of wastewater monitoring, compared to older, suburban dwellers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a grant from The Rockefeller Foundation, as well as grants from the James Graham Brown Foundation and the Owsley Brown II Family Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Louisville Institutional Review Board approved this project as Human Subjects Research (IRB number: 21.0877).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
